Skip to main content

Advertisement

SpringerLink
Log in

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

  • Clinical Trial
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Imatinib mesylate is used as first line therapy in the treatment of chronic myeloid leukaemia. This study was designed to study the correlation of plasma levels of imatinib with response to the therapy.

Methods

A total of 40 chronic myeloid leukaemia patients in the chronic phase of the disease were recruited and placed into two groups of 20 patients: imatinib responders and imatinib non-responders, respectively. Each blood sample was taken 24 h after and immediately prior to taking a 400 mg oral dose of imatinib. Drug levels were detected by high-performance liquid chromatography.

Results

The mean plasma imatinib levels in the imatinib non-responders were significantly lower than those in the imatinib responders (0.70 vs. 2.34 µM, respectively; p = 0.002).

Conclusions

Plasma levels of imatinib were correlated with response to the therapy, so routine monitoring of the therapeutic levels of the drug should be carried out specifically in treatment-resistant cases for determining dose escalation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340

    Article  PubMed  CAS  Google Scholar 

  2. Kumar L (2006) Chronic myelogenous leukemia (CML): an update. Nat Med J India 19:255–263

    Google Scholar 

  3. Peggs K, Mackinnon S (2003) Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048–1050

    Article  PubMed  Google Scholar 

  4. Gambacorti-Passerini CB, Gunby RH, Kaeda J (2003) Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukaemias. Lancet Oncol 4:75–85

    Article  PubMed  Google Scholar 

  5. Druker BJ, Tamura S, Buchdunger E (1996) Effects of a selective inhibitors of the Abl tyrosinekinase on the growth of BCR–ABL positive cells. Nat Med 2:561–566

    Article  PubMed  CAS  Google Scholar 

  6. Cancer Care Ontario (2008) Revised Drug formulary. Available via DIALOG: http://www.cancercare.on.ca/pdfdrugs/Imatinib—Mesylate.pdf Accessed 12 Aug 2008

  7. le Coutre P, O’Dwyer ME, Druker BJ (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313–323

    Article  PubMed  Google Scholar 

  8. Larson RA, Druker BJ, Guilhot F (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–4028

    Article  PubMed  CAS  Google Scholar 

  9. Velpandian T, Kumar L, Arora B (2004) Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinb in biological samples. J Chromatogr B 804:431–434

    Article  CAS  Google Scholar 

  10. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894

    Article  PubMed  CAS  Google Scholar 

  11. Picard S, Titier K, Etienne G (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses for standard dose imatinib in chronic myeloid leukemia. Blood 109:3496–3499

    Article  PubMed  CAS  Google Scholar 

  12. Branford S, Rudzki Z, Walsh S (2003) Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis. Blood 102:276–283

    Article  PubMed  CAS  Google Scholar 

  13. Jabbour E, Kantarjian H, Jones D (2006) Frequency and clinical significance of BCR–ABL mutations in patients with chronic myeloid leukaemia treated with imatinib mesylate. Leukemia 20:1767–1773

    Article  PubMed  CAS  Google Scholar 

  14. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475–490

    Article  PubMed  CAS  Google Scholar 

  15. Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192–199

    Article  PubMed  CAS  Google Scholar 

  16. Illmer T, Schaich M, Platzbecker (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukaemia cells to treatment with imatinib mesylate. Leukemia 18:401–408

    Article  PubMed  CAS  Google Scholar 

  17. Thomas J, Wang L, Clark RE (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739–3745

    Article  PubMed  CAS  Google Scholar 

  18. Wei Y, Hardling M, Olsson B (2006) Not all imatinib resistance in CML are BCR–ABL kinase domain mutations. J Clin Pharm 85:841–847

    CAS  Google Scholar 

  19. Rais N, Chawla YK, Kohli KK (2006) CYP3A phenotypes and genotypes in north indians. Eur J Clin Pharm 62:417–422

    Article  CAS  Google Scholar 

  20. Lamba V, Lamba JK, Dilawari JB (1988) Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharm 54:9–11

    Google Scholar 

  21. Crossman LC, Druker BJ, Deininger MWN (2005) HOCT1 and resistance to imatinib. Blood 106:1133–1134

    Article  PubMed  CAS  Google Scholar 

  22. Kantarjian HM, Talpaz M, OBrien S (2008) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with CML. Blood 101:473–475

    Article  Google Scholar 

Download references

Acknowledgements

We thank Dr. Alok K Ravi for helping us in with the HPLC operations

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

    N. Singh & L. Kumar

  2. Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 110029, India

    R. Meena

  3. Ocular Pharmacology and Pharmacy, Dr. R.P. Centre for Opthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 110029, India

    T. Velpandian

Authors
  1. N. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Meena
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Velpandian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, N., Kumar, L., Meena, R. et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65, 545–549 (2009). https://doi.org/10.1007/s00228-009-0621-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0621-z

Keywords

Search

Navigation